-
New Clinical Trial Explores Amino Acid Supplements to Help Dialysis Patients Feel Stronger
A new study is testing whether oral amino acid supplements taken during hemodialysis can reduce fatigue and frailty in patients with end-stage kidney disease.
-
New Clinical Trial Explores Novel CCH Protocol for Peyronie’s Disease Non-Responders
A new study is investigating whether a modified collagenase clostridium histolyticum (CCH) treatment protocol can help men with Peyronie’s disease who didn’t respond to earlier CCH therapy.
-
New Trial Explores Adding Immunotherapy to Boost Breast Cancer Treatment Response
A newly launched clinical trial is testing whether combining the immunotherapy QL1706 with standard endocrine therapy can help breast cancer patients who didn’t respond well to initial chemotherapy. The study offers a potential new option for a challenging-to-treat patient group.
-
New Phase 2 Trial Explores Adding Pelareorep to Standard Therapy for Advanced Colorectal Cancer
A new open-label Phase 2 study will test whether adding the investigational agent pelareorep to standard FOLFIRI plus bevacizumab improves outcomes for patients with RAS-mutated, microsatellite-stable metastatic colorectal cancer.
-
University of Cincinnati Begins Clinical Trial Targeting Prosthetic Joint Infections
The University of Cincinnati has enrolled its first patients in a new clinical trial aimed at improving treatment for prosthetic joint infections, a persistent challenge in orthopedic care.
-
FDA Advisory Panel Gives Nod to Six Promising Peptides
An FDA advisory panel has expressed support for six peptides, a signal that could pave the way for broader research and future access to these compounds.
-
TearSolutions’ Peptide Therapy Lacripep Moves Into Phase 2 Trial for Neurotrophic Keratitis
TearSolutions is advancing its lacritin-based peptide candidate Lacripep into a Phase 2 clinical trial for neurotrophic keratitis after receiving two supportive FDA designations. The milestone highlights growing momentum for peptide-based approaches to treating serious eye surface disease.
-
Croatian Scientists’ 1990s Peptide Discovery Gains Mainstream Attention in the US
A peptide first identified by Croatian researchers decades ago is now drawing significant interest in the United States, highlighting how foundational science can find new life and application years after its initial discovery.
-
Kither Biotech Completes Phase I Trial for Novel Peptide Therapy KIT2014
Kither Biotech has announced the completion of a Phase I clinical trial for its investigational peptide therapy KIT2014, marking an important step forward in the compound’s development.
-
FDA Panel Set to Reconsider Peptide Restrictions, Signaling Potential for Expanded Access
An FDA panel is expected to revisit prior restrictions on certain peptides, opening the door to potentially more accessible pathways for these compounds. The move suggests regulators are open to reassessing earlier policy decisions.